Liraglutide

Long-acting acylated glucagon-like peptide-1 (GLP-1) receptor agonist.
Antidiabetic and antiobesity agent used clinically to treat type 2 diabetes mellitus. Binding to GLP-1R, activates AMP-activated protein kinase, consequently stimulates insulin secretion in pancreatic β cells and suppresses glucagon secretion in a glucose-dependent manner. Improves control of blood glucose and consequently modulates appetite and body weight.
Inhibits β cell apoptosis and improves β cell mass.
Shown to ameliorate glycometabolism and insulin resistance through the upregulation of GLUT4.
Neuroprotective. Prevents neurodegenerative processes in pathologies such as Alzheimer's and Parkinson's disease.
Anti-inflammatory agent. Exerts cardioprotective roles via activating prosurvival pathways and suppressing inflammation. Anti-pyroptotic by inhibiting TNF-α and hypoxia-induced inflammasome activation.
Anticancer agent. Inhibited proliferation and induced apoptosis in cancer cell lines.
Shown to inhibit osteoclastogenesis.